Loading...
01/10 16:05
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented mixed signals. While there are positive developments like the potential revenue from Sildenafil Cream and strategic partnerships, there are notable risks including supply chain challenges and clinical trial uncertainties. The Q&A section highlighted concerns about manufacturing readiness and FDA feedback, which could delay product timelines. Financially, there is a working capital deficit and comprehensive loss, but reduced expenses are a positive sign. Without a market cap, the stock's reaction is uncertain, but the mixed outlook suggests a neutral impact on stock price over the next two weeks.
General and Administrative Expenses $2,300,000 (14% decrease year-over-year) due to reduced stock-based compensation, reduced personal professional services expense, and reduced headcount.
Research and Development Expenses $2,300,000 (31% decrease year-over-year) due to varying clinical, preclinical, manufacturing, regulatory, and other development program costs.
Comprehensive Loss $4,400,000 for the quarter.
Cash and Cash Equivalents $10,300,000 at the end of the first quarter.
Working Capital Deficit Approximately $9,400,000.
Shares Outstanding Approximately 8,900,000 shares of common stock.
New Products: Dare Bioscience is launching three new solutions for women: two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026, alongside their Sildenafil Cream formulation.
Market Expansion: The hormone therapy solution targets the $4.5 billion compounded hormone therapy market, aiming to provide women with evidence-based solutions.
Operational Efficiencies: General and administrative expenses decreased by 14% to approximately $2.3 million, and R&D expenses decreased by 31% to approximately $2.3 million compared to Q1 2024.
Revenue Generation: Dare expects to start recording revenue in Q4 2025.
Strategic Shifts: Dare is adopting a dual path strategy to commercialize proprietary formulations via 503B compounding while seeking FDA approval, and launching certain solutions as branded consumer health products.
Regulatory Risks: Dare Bioscience is pursuing a dual path strategy for commercialization, which includes seeking FDA approval while also utilizing the 503B compounding pathway. This approach carries risks related to regulatory compliance and the potential for delays in FDA approval.
Financial Risks: The company reported a comprehensive loss of approximately $4,400,000 for the first quarter of 2025 and has a working capital deficit of approximately $9,400,000, indicating financial strain that could impact operations and growth.
Market Risks: Dare is entering a competitive market for women's health products, particularly in the compounded hormone therapy market, which is estimated at $4,500,000,000. The success of their products will depend on market acceptance and competition from established players.
Supply Chain Challenges: The company must ensure that its 503B manufacturing partner is prepared to produce its proprietary Sildenafil Cream and other products at scale, which involves significant preparation and compliance with GMP regulations.
Partnership Risks: Dare plans to establish multiple partnerships for product distribution, which introduces risks related to the reliability and effectiveness of these partnerships in reaching target markets.
Clinical Development Risks: The ongoing clinical trials, such as for Ovaprene and Sildenafil Cream, carry inherent risks of failure or delays, which could impact the timeline for product availability and revenue generation.
Expanded Business Strategy: Dare is leveraging a dual path strategy to commercialize proprietary formulations via 503B compounding while seeking FDA approval and launching certain solutions as branded consumer health products.
Commercial Opportunity: The hormone therapy solution is expected to create a commercial opportunity in the estimated $4.5 billion compounded hormone therapy market.
Revenue Generation: Dare expects to start recording revenue in the fourth quarter of 2025.
Partnership Strategy: Dare plans to establish multiple strategic partnerships to facilitate access to their products across various channels.
Product Pipeline: Dare is developing several products including Sildenafil Cream, monthly hormone therapy, and vaginal probiotics, with plans to bring them to market in 2025 and 2026.
Financial Outlook: Dare anticipates a comprehensive loss of approximately $4.4 million for Q1 2025 and ended the quarter with approximately $10.3 million in cash.
R&D Expenses: R&D expenses for Q1 2025 were approximately $2.3 million, a 31% decrease compared to Q1 2024.
Future Financial Projections: Dare is focused on building shareholder value and expects to monetize its portfolio's clinical and regulatory advances over the near and long term.
Shares Outstanding: As of 05/12/2025, we had approximately 8,900,000.0 shares of common stock outstanding.
Cash and Cash Equivalents: We ended the first quarter with approximately $10,300,000 in cash and cash equivalents.
Working Capital Deficit: We ended the first quarter with a working capital deficit of approximately $9,400,000.
Comprehensive Loss: Our comprehensive loss for the quarter was approximately $4,400,000.
General and Administrative Expenses: During the first quarter of twenty twenty five, our general and administrative expenses were approximately $2,300,000.
R&D Expenses: Our R&D expenses were approximately $2,300,000 which is a 31% decrease compared to Q1 twenty twenty four.
Investment in Shareholder Value: Dare remains committed to being creative, collaborative and opportunistic to build shareholder value, including by making certain proprietary formulations in the Dare portfolio accessible via a prescription through the FDA’s 503B pathway.
Revenue Generation Expectation: We expect to start recording revenue in the fourth quarter of this year.
Market Opportunity: Making our hormone therapy solution available next year creates a commercial opportunity for Dare in the estimated up to $4,500,000,000 compounded hormone therapy market.
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
The earnings call presents several concerns: regulatory risks with the dual path strategy, financial instability due to a working capital deficit, and increased market competition. While there is optimism regarding partnerships and product development, the lack of immediate revenue, comprehensive losses, and unclear management responses in the Q&A section contribute to a negative sentiment. The financial health and shareholder return plans are notably weak, and the absence of immediate catalysts or strong financial performance suggests a likely negative stock price reaction.
The earnings call presented mixed signals. While there are positive developments like the potential revenue from Sildenafil Cream and strategic partnerships, there are notable risks including supply chain challenges and clinical trial uncertainties. The Q&A section highlighted concerns about manufacturing readiness and FDA feedback, which could delay product timelines. Financially, there is a working capital deficit and comprehensive loss, but reduced expenses are a positive sign. Without a market cap, the stock's reaction is uncertain, but the mixed outlook suggests a neutral impact on stock price over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
